News | Cardiovascular Ultrasound | June 15, 2022

Cardiawave Confirms the Safety of VALVOSOFT its Non-Invasive Ultrasound Treatment for Aortic Stenosis

Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking

Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke

June 15, 2022 — Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke.

This final phase of the clinical study “Valvosoft FIM STUDY” (FIM II) showed no signs of any cerebral vascular anomaly in the 10 patients treated. This marks the completion of two successful First-In-Human clinical studies involving a total of 40 patients treated in France, the Netherlands and Serbia.

“This confirmation of the safety of Valvosoft bodes well for the launch of patient recruitment for our European pivotal study which will commence shortly in France, and extended to Germany and the Netherlands, with the aim of obtaining CE Marking.” said Benjamin Bertrand, CEO of Cardiawave.

Valvosoft’s non-invasive treatment brings great hope for patients with aortic stenosis and for their families. Having the absence of any abnormality before and after treatment being confirmed by MRI scans is major clinical step forward” declared Professeur Emmanuel Messas the Georges Pompidou European Hospital (AP-HP), in Paris.

For more information: www.cardiawave.com

 


Related Content

Videos | Cardiac Imaging

Artificial intelligence and general consolidation were two top cardiology trends at RSNA22. ITN/DAIC spoke with Val ...

Home January 23, 2023
Home
News | Cardiac Imaging

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

Home January 13, 2023
Home
News | Cardiac Imaging

November 29, 2022 — Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10 ...

Home November 29, 2022
Home
News | Cardiac Imaging

November 28, 2022 – UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power ...

Home November 28, 2022
Home
News | Cardiac Imaging

November 28, 2022 — Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare ...

Home November 28, 2022
Home
Feature | Cardiac Imaging

Discover the key features of cardiovascular structured reporting that drive adoption, including automated data flow, EHR ...

Home November 07, 2022
Home
News | Cardiac Imaging

October 18, 2022 — HeartFlow, Inc., a leader in revolutionizing precision heart care, has received U.S. Food and Drug ...

Home October 18, 2022
Home
Webinar | Cardiac Imaging

The direct impact of COVID-19 is substantial. The resulting impact of the pandemic has forced healthcare organizations ...

Home October 17, 2022
Home
News | Cardiac Imaging

October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain features ...

Home October 11, 2022
Home
News | Cardiac Imaging

September 2, 2022 — A randomized trial in more than 45,000 men has suggested that cardiovascular screening including ...

Home September 02, 2022
Home
Subscribe Now